CA
NZ
UK
AU
IND
US
Apollomics Inc., a clinical-stage biopharmaceutical company focused on oncology drug development, declined on June 23, 2026, as a broad market risk-off event extended selling pressure across small-cap growth stocks including clinical-stage biotechs with no near-term revenue.
Fennec Pharmaceuticals (NASDAQ:FENC) rose 8.08% on June 23, 2026, closing at $10.30 after a $0.77 per-share move. The session’s advance came as PEDMARK commercial uptake supported the orphan-drug stock, based on the available company disclosures and trading context.
Evommune (NASDAQ:EVMN) rose 7.54% on June 23, 2026, closing at $24.25 after a $1.70 per-share move. The session’s advance came as clinical milestone anticipation lifted the dermatology biotech, based on the available company disclosures and trading context.
GH Research (NASDAQ:GHRS) rose 6.88% on June 23, 2026, closing at $23.61 after a $1.52 per-share move. The session’s advance came as psychiatric trial publication sustained clinical optimism, based on the available company disclosures and trading context.
Edesa Biotech (NASDAQ:EDSA) rose 12.19% on June 23, 2026, closing at $7.64 after a $0.83 per-share move. The session’s advance came as government-backed inflammation programme drew biotech buyers, based on the available company disclosures and trading context.
Akanda (NASDAQ:AKAN) rose 7.37% on June 23, 2026, closing at $16.18 after a $1.11 per-share move. The session’s advance came as technical rebound offset Nasdaq compliance concerns, based on the available company disclosures and trading context.
ClearPoint Neuro (NASDAQ:CLPT) rose 8.62% on June 23, 2026, closing at $18.53 after a $1.47 per-share move. The session’s advance came as gene therapy delivery demand supported the neurosurgical platform, based on the available company disclosures and trading context.
Cue Biopharma Inc., a clinical-stage cancer immunotherapy company, declined on June 23, 2026, as a broad macro risk-off event extended selling pressure across clinical-stage biotechs with no company-specific catalyst driving the session.Key HighlightsCue Biopharma declined on June 23 alongside the broader clinical-stage oncology sector …
Cardio Diagnostics (NASDAQ:CDIO) rose 11.68% on June 23, 2026, closing at $2.20 after a $0.23 per-share move. The session’s advance came as AI diagnostics interest drove speculative micro-cap demand, based on the available company disclosures and trading context.
Tvardi Therapeutics, which began trading following a reverse merger with the former Cara Therapeutics entity, declined on June 23, 2026, as a broad macro risk-off event weighed on small-cap clinical-stage biotechs across all disease areas.
Please wait processing your request...